Related Experiment Videos

[Evaluation of survival in mixed connective tissue disease (MCTD)]

Edit Bodolay1, János Gaál, Judit Végh

  • 1Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Altalános Orvostudományi Kar, Országos Immunológiai Koordinációs Intézet. bodolai@iiibel.dote.hu

Orvosi Hetilap
|December 28, 2002
PubMed
Abstract

Insights

Patients with mixed connective tissue disease (MCTD) have a good prognosis, with 15-year survival rates approaching 90%. Pulmonary hypertension is the leading cause of death, emphasizing its role as a critical prognostic factor in MCTD patient outcomes.

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Context:

  • Mixed Connective Tissue Disease (MCTD) is a complex autoimmune disorder.
  • Long-term survival data and causes of mortality in MCTD patients are crucial for clinical management.
  • Understanding prognostic factors is essential for improving patient outcomes.

Purpose:

  • To analyze the survival rates and causes of death in a cohort of 179 patients with MCTD.
  • To identify the most significant prognostic factors influencing mortality in MCTD.
  • To compare the observed survival rates with existing literature data.

Summary:

  • Kaplan-Meier survival analysis of 179 MCTD patients over a mean follow-up of 13.1 years revealed 5-, 10-, and 15-year survival rates of 96.4%, 93.9%, and 89.6%, respectively.
  • Pulmonary hypertension was the primary cause of death in 5 patients, followed by thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (3 cases) and infections (3 cases).
  • Pulmonary hypertension, characterized by rapid development, endothelial proliferation, and microangiopathy, emerged as the most critical prognostic factor.

Impact:

  • The study highlights the significant impact of pulmonary hypertension on MCTD mortality.
  • Findings suggest that improved survival rates in this cohort may be attributed to genetic-demographic factors and diligent patient follow-up.
  • This research provides valuable insights for clinicians managing MCTD patients, particularly regarding early detection and management of pulmonary hypertension and infections.

Related Concept Videos